Guggenheim Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.8M | Buy |
39,318
+2,204
| +6% | +$665K | 0.07% | 252 |
|
|
2026
Q1 | $12.3M | Sell |
37,114
-3,021
| -8% | -$1.03M | 0.1% | 230 |
|
|
2025
Q4 | $16M | Buy |
40,135
+31,510
| +365% | +$13.9M | 0.11% | 172 |
|
|
2025
Q3 | $3.93M | Sell |
8,625
-2,024
| -19% | -$824K | 0.03% | 506 |
|
|
2025
Q2 | $3.47M | Sell |
10,649
-1,718
| -14% | -$475K | 0.03% | 515 |
|
|
2025
Q1 | $3.34M | Sell |
12,367
-416
| -3% | -$107K | 0.03% | 518 |
|
|
2024
Q4 | $3.01M | Sell |
12,783
-2,465
| -16% | -$648K | 0.02% | 539 |
|
|
2024
Q3 | $4.19M | Sell |
15,248
-3,939
| -21% | -$1.03M | 0.03% | 586 |
|
|
2024
Q2 | $4.66M | Sell |
19,187
-1,975
| -9% | -$312K | 0.03% | 546 |
|
|
2024
Q1 | $3.16M | Buy |
21,162
+3,411
| +19% | +$569K | 0.02% | 730 |
|
|
2023
Q4 | $3.4M | Buy |
17,751
+507
| +3% | +$86.4K | 0.03% | 666 |
|
|
2023
Q3 | $3.05M | Sell |
17,244
-2,422
| -12% | -$462K | 0.03% | 666 |
|
|
2023
Q2 | $3.74M | Sell |
19,666
-320
| -2% | -$63.4K | 0.03% | 633 |
|
|
2023
Q1 | $4M | Sell |
19,986
-831
| -4% | -$175K | 0.03% | 605 |
|
|
2022
Q4 | $4.95M | Buy |
20,817
+1,560
| +8% | +$333K | 0.04% | 534 |
|
|
2022
Q3 | $3.85M | Sell |
19,257
-6,092
| -24% | -$1.16M | 0.04% | 594 |
|
|
2022
Q2 | $3.7M | Sell |
25,349
-395
| -2% | -$56K | 0.03% | 667 |
|
|
2022
Q1 | $4.2M | Sell |
25,744
-561
| -2% | -$85.5K | 0.03% | 716 |
|
|
2021
Q4 | $4.46M | Buy |
26,305
+2,461
| +10% | +$457K | 0.02% | 730 |
|
|
2021
Q3 | $4.5M | Sell |
23,844
-2,093
| -8% | -$393K | 0.03% | 706 |
|
|
2021
Q2 | $4.4M | Sell |
25,937
-3,501
| -12% | -$513K | 0.03% | 724 |
|
|
2021
Q1 | $4.16M | Sell |
29,438
-2,205
| -7% | -$332K | 0.03% | 712 |
|
|
2020
Q4 | $4.11M | Sell |
31,643
-6,401
| -17% | -$855K | 0.03% | 668 |
|
|
2020
Q3 | $5.54M | Sell |
38,044
-7,104
| -16% | -$1.01M | 0.04% | 487 |
|
|
2020
Q2 | $6.69M | Buy |
45,148
+3,330
| +8% | +$449K | 0.05% | 403 |
|
|
2020
Q1 | $4.55M | Sell |
41,818
-9,187
| -18% | -$1.06M | 0.05% | 478 |
|
|
2019
Q4 | $5.87M | Buy |
51,005
+315
| +0.6% | +$31.4K | 0.04% | 542 |
|
|
2019
Q3 | $4.08M | Sell |
50,690
-7,433
| -13% | -$588K | 0.03% | 685 |
|
|
2019
Q2 | $4.22M | Sell |
58,123
-2,134
| -4% | -$164K | 0.03% | 696 |
|
|
2019
Q1 | $5.63M | Sell |
60,257
-3,717
| -6% | -$311K | 0.05% | 549 |
|
|
2018
Q4 | $4.66M | Buy |
63,974
+3,473
| +6% | +$267K | 0.04% | 609 |
|
|
2018
Q3 | $5.29M | Buy |
60,501
+4,680
| +8% | +$471K | 0.03% | 692 |
|
|
2018
Q2 | $5.5M | Buy |
55,821
+2,737
| +5% | +$271K | 0.04% | 658 |
|
|
2018
Q1 | $6.32M | Buy |
53,084
+600
| +1% | +$77.4K | 0.02% | 883 |
|
|
2017
Q4 | $6.67M | Sell |
52,484
-32,983
| -39% | -$4.14M | 0.02% | 884 |
|
|
2017
Q3 | $10M | Buy |
85,467
+18,094
| +27% | +$1.54M | 0.02% | 681 |
|
|
2017
Q2 | $5.38M | Sell |
67,373
-17,484
| -21% | -$1.12M | 0.01% | 975 |
|
|
2017
Q1 | $4.35M | Buy |
84,857
+5,774
| +7% | +$267K | 0.01% | 1109 |
|
|
2016
Q4 | $2.96M | Buy |
79,083
+4,565
| +6% | +$191K | 0.01% | 1379 |
|
|
2016
Q3 | $5.05M | Sell |
74,518
-11,850
| -14% | -$836K | 0.02% | 1011 |
|
|
2016
Q2 | $4.79M | Sell |
86,368
-4,294
| -5% | -$271K | 0.02% | 1028 |
|
|
2016
Q1 | $5.69M | Sell |
90,662
-23,340
| -20% | -$1.55M | 0.02% | 920 |
|
|
2015
Q4 | $10.7M | Sell |
114,002
-28,541
| -20% | -$2.65M | 0.03% | 733 |
|
|
2015
Q3 | $11.5M | Sell |
142,543
-2,220
| -2% | -$247K | 0.04% | 701 |
|
|
2015
Q2 | $17.4M | Buy |
144,763
+8,423
| +6% | +$1.01M | 0.04% | 644 |
|
|
2015
Q1 | $14.2M | Buy |
136,340
+22,323
| +20% | +$2.26M | 0.03% | 724 |
|
|
2014
Q4 | $11.1M | Buy |
114,017
+14,441
| +15% | +$1.34M | 0.03% | 801 |
|
|
2014
Q3 | $7.78M | Sell |
99,576
-4,254
| -4% | -$274K | 0.02% | 1000 |
|
|
2014
Q2 | $6.56M | Sell |
103,830
-10,627
| -9% | -$632K | 0.02% | 1039 |
|
|
2014
Q1 | $7.68M | Buy |
114,457
+13,710
| +14% | +$1.06M | 0.02% | 937 |
|
|
2013
Q4 | $6.48M | Sell |
100,747
-7,349
| -7% | -$438K | 0.02% | 981 |
|
|
2013
Q3 | $6.92M | Sell |
108,096
-73,320
| -40% | -$3.65M | 0.02% | 951 |
|
|
2013
Q2 | $5.63M | Buy |
+181,416
| New | +$4.83M | 0.02% | 1003 |
|
Other funds holding ALNY
Guggenheim Capital's ALNY Position: Q2 2026 in Review
Guggenheim Capital increased its Alnylam Pharmaceuticals (ALNY) stake by 5.9% in Q2 2026, buying an estimated $665K and bringing the position to 39,318 shares worth $11.8M. The position accounts for 0.07% of the portfolio, ranked #252.
Guggenheim Capital first reported a position in ALNY in Q2 2013 and has held it in 53 quarters since. The position peaked at $17.4M in Q2 2015. 786 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Guggenheim Capital held 39,318 shares of Alnylam Pharmaceuticals worth $11.8M as of Q2 2026.
- Guggenheim Capital bought 2,204 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $665K.
- Alnylam Pharmaceuticals made up 0.07% of Guggenheim Capital's portfolio in Q2 2026, its #252 holding.
- Guggenheim Capital first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Guggenheim Capital's Alnylam Pharmaceuticals position peaked at $17.4M in Q2 2015.
- 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.